Matinas BioPharma Holdings (MTNB) Share-based Compensation (2013 - 2026)
Matinas BioPharma Holdings (MTNB) reported Share-based Compensation of $113000.0 for Q1 2026, down 64.13% year-over-year from $315000.0 in Q1 2025, and down 47.93% quarter-over-quarter from $217000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Share-based Compensation (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 14 years of Share-based Compensation data on file, last reported at $113000.0 in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $113000.0, down 64.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $821000.0 (down 67.36% YoY), and the FY2025 annual result was $1.0 million, down 67.98% from the prior year.
- Share-based Compensation retreated to $113000.0 in Q1 2026 per MTNB's latest filing, from $217000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.4 million in Q3 2022 and troughed at $113000.0 in Q1 2026.
- A 5-year average of $853352.9 and a median of $995000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 33.18% in 2022, then tumbled 80.82% in 2024.
- A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2022, then declined by 5.07% to $1.3 million in 2023, then plunged by 80.82% to $244000.0 in 2024, then declined by 11.07% to $217000.0 in 2025, then plunged by 47.93% to $113000.0 in 2026.
- Business Quant data shows MTNB's Share-based Compensation at $113000.0 in Q1 2026, $217000.0 in Q4 2025, and $253000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | 113,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 113,000.00 |
| Mar 31, 2026 | 113,000.00 |
| Dec 31, 2025 | 217,000.00 |
| Dec 31, 2025 | 217,000.00 |
| Sep 30, 2025 | 253,000.00 |
| Sep 30, 2025 | 253,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Dec 31, 2024 | 244,000.00 |
| Dec 31, 2024 | 244,000.00 |
| Sep 30, 2024 | 965,000.00 |
| Sep 30, 2024 | 965,000.00 |
| Jun 30, 2024 | 991,000.00 |
| Jun 30, 2024 | 991,000.00 |
| Mar 31, 2024 | 995,000.00 |
| Mar 31, 2024 | 995,000.00 |
| Dec 31, 2023 | 1.27 Mn |
| Dec 31, 2023 | 1.27 Mn |